百克生物：2025年度净亏损2.72亿元

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the fiscal year 2025, primarily influenced by various factors affecting public awareness and willingness to consume vaccines [1] Financial Performance - Total operating revenue for the year was 592 million yuan, representing a year-on-year decrease of 51.85% [1] - Net profit attributable to the parent company was -272 million yuan, a year-on-year decline of 217.22% [1] - Net profit attributable to the parent company, excluding non-recurring gains and losses, was -289 million yuan, reflecting a year-on-year decrease of 225.71% [1] Factors Influencing Performance - The decline in revenue was attributed to several factors, including public awareness of diseases and willingness to receive vaccinations [1] - The company faced returns on confirmed revenue from the herpes zoster live attenuated vaccine due to expiration before administration, contributing to the revenue drop [1] - To enhance public awareness of herpes zoster prevention and fulfill corporate social responsibility, the company actively promoted welfare projects and adjusted prices, leading to a decrease in the unit price of the herpes zoster vaccine, which further impacted revenue [1] - Additionally, a decline in newborn birth rates and increased market competition resulted in reduced sales of the varicella live attenuated vaccine, further contributing to the revenue decline [1]